Prueba landing

LABSINLOVE

When cancer isn’t the end

We develop boron-based drugs that make Boron Neutron Capture Therapy (BNCT) more selective, safer and scalable, for patients with advanced cancers who have run out of options.

Spin-off of the University of Granada and CSIC. Founded in 2023, based in Granada.

Problem

Patients with advanced cancers are out of options and out of time

Most of these patients have exhausted standard treatments: surgery, radiotherapy and chemotherapy. Their only option is palliative care.

15–20%of patients respond to immunotherapy. The rest don’t respond or relapse quickly.

250,000+patients a year in the EU and US face aggressive, poor-prognosis cancers with no curative path.

5-year survival rate

All tumour types55%

Triple negative breast12%

Recurrent head and neck10%

NE lung cancer10%

Glioblastoma7%

DIPG (paediatric)1%

Solution

Boron Neutron Capture Therapy (BNCT)

Boron compound
A boron drug (BPA) is administered and reaches the tumour.
Neutron irradiation
The tumour is irradiated with neutrons.
Cell destruction
The capture reaction releases particles that destroy the tumour cell.

Selective radiotherapy in one day

For advanced cancer patients, survival is measured in months. BNCT offers a targeted treatment in a single day.

Technology

BOROPEPT: precision boron drugs for each cancer type

Current boron carriers (BPA) have limited tumour selectivity, uneven distribution, short retention and no molecular targeting. BOROPEPT, our patented family of boron cluster–peptide conjugates, is designed to select cancer cells and can be adapted to new tumour types.

BOROPEPT: boron-cluster carriers linked to a peptide analog that binds an overexpressed receptor on the tumour cell

Lil-1Lung cancerCurrent focus

Lil-2GlioblastomaCurrent focus

Lil-3Breast cancerPipeline

Lil-4Paediatric (DIPG and medulloblastoma)Pipeline

Team

Experts in BNCT and in biotech management

Cristina Aguilera Xiol, PhD

CEO

PhD in Biomedicine. Biotech management, ex-Novartis and Lilly.

Prof. Ignacio Porras Sánchez, PhD

Co-founder and CSO

University of Granada. Vice President of the International Society for Neutron Capture Therapy.

Prof. Carmen Ruiz-Ruiz, PhD

Co-founder, Head of Biology Lab

Professor of Immunology, University of Granada. Neutron radiobiology.

Prof. Rosario Núñez Aguilera, PhD

Co-founder, Head of Chemistry Lab

ICMAB-CSIC, Barcelona. Boron cluster chemistry.

Maria Isabel Porras Quesada

PhD student

University of Granada.

Miquel Nuez Martinez, PhD

Postdoctoral researcher

PhD in Boron Chemistry, ICMAB Barcelona.

Advisors

Yuan-Hao Liu, PhD

Science

CSO of Neuboron Medtech.

Silva Bortolussi, PhD

Science

Professor of Medical Physics, University of Pavia.

José Expósito

Medical

Head of radiation oncology, Hospital Virgen de las Nieves, Granada.

Juan Pablo Nebrera Salcedo

Business

Co-founder and CEO of Brooklyn Fitboxing.

Funding

Publicly funded research

Our R&D is cofunded by Andalucía Trade with EU funds (grant 4IIDE2400014) and by the Agencia Estatal de Investigación, Ministerio de Ciencia, Innovación y Universidades (grants PTQ2023-013166, DIN2024-013389 and PTQ2025-014556).

Enter your text here...